This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials.
JAMA network open. 2021 May 03*** epublish ***
Christopher J D Wallis, Zachary Klaassen, William C Jackson, Robert T Dess, Zachery R Reichert, Yilun Sun, Daniel E Spratt
Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Surgery, Division of Urology, Medical College of Georgia at Augusta University, Augusta., Department of Radiation Oncology, University of Michigan, Ann Arbor., Department of Medicine, University of Michigan, Ann Arbor.